Actions of dolasetron and its major metabolite on guinea-pig papillary muscle fibres and the α-subunit of human heart sodium channels expressed in Xenopus oocytes

Drug Development Research

Volumn 37, Issue 4, 1996, Pages 223-230

  Dumaine, Robert ^a   Hartmann, Hali A ^c   Leishman, Derek J ^b,d   Brown, Arthur M ^a   Galvan, Martin ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b SANOFI   (France)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

5 HT3 receptor; Antiemetic; ECG; Flecainide

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DOLASETRON MESILATE; FLECAINIDE; HYDRODOLASETRON; MDL 73405; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG PROTEIN BINDING; GUINEA PIG; HEART DEPOLARIZATION; HEART MUSCLE POTENTIAL; HUMAN; MALE; NONHUMAN; OOCYTE; XENOPUS;

EID: 0030056512     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199604)37:4<223::AID-DDR4>3.0.CO;2-N     Document Type: Article

References (27)

1. Baltzer L, Kris MG, Hinkley L, Pisters KMW, Lacava PV, Pierri MK, Rigas JR, Grant SC, Gralla RJ, Grunberg S, Hahne W (1994): Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): A possible drug class effect without sequelae? Proc ASCO 13:433.
2. 3 receptor antagonist. Drug Dev Res 34:289-296.
3. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 219: 9-13.
4. Boxenbaum H, Gillespie T, Heck K, Hahne W (1992). Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 13:693-701.
5. Boxenbaum H, Gillespie T, Heck K, Hahne W (1993): Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects. Biopharm Drug Dispos 14:131-141.
6. Campbell TJ (1989): Subclassification of Class I antiarrhythmic drugs. In Vaughan Williams EM (ed): Antiarrhythmic Drugs. Berlin: Springer-Verlag, pp 136-155.
7. Campbell T, Williams E (1983): Voltage- and time-dependent depression of maximum rate of depolarization of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res 17:251-258.
8. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 17:97-102.
9. 3 antagonists, ondansetron and granisetron, in feline ventricular myocytes Br J Pharmacol 113: 527-535.
10. Dow J, Berg C (1995): Stereoselectivity of the carbonyl reduction of dolasetron in rats, dogs and humans. Chirality 7:342-348.
11. Drewe JA, Hartmann HA, Kirsch GE (1994): Potassium channels in mammalian brain: A molecular approach. In Narahashi T (ed): Methods in Neuroscience. San Diego: Academic Press, Vol 17, pp 243-260.
12. + inactivation gating. Circ Res 75:114-122.
13. Hof RP, Hof A, Novosel D, Zierhut W (1993): Antiarrhythmic and hemodynamic effects of tropisetron in anesthetized rabbits. J Cardiovasc Pharmacol 22:499-505.
14. Kojima M, Hamamoto T, Ban T (1989): Sodium channel blocking properties of flecainide, a class 1C antiarrhythmic drug, in guinea-pig papillary muscles. Naunyn Schmiedebergs Arch Pharmacol 339:441-447.
15. Konzen G, Reichardt B, Hauswirth O (1990): Fast and slow blockade of sodium channels by flecainide in rabbit cardiac Purkinje fibers. Naunyn Schmiedebergs Arch Pharmacol 341:565-576.
16. Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, Tyson LB, Schmidt L, Hahne WF (1994): Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049.
17. Lifsey DS, Gralla RJ, Clark RA, Kline RC (1993): Electrocardiographic changes with serotonin antagonist antiemetics: Rate of occurrence and clinical relevance. Proc ASCO 12:463.
18. 3 receptors. Drug Dev Res 28:87-93.
19. Morganroth J, McGinn C (1988): Antiarrhythmic effects of a 5-hydroxytryptamine M-receptor antagonist ICS 205-930. Am J Cardiol 61:470-471.
20. 3 receptors. TIPS 13:391-397.
21. Rusthoven J, Pater J, Kaizer L, Wilson K, Osoba D, Latreille J, Findlay B, Lofters WS, Warr D, Laberge F, Vandenberg T, Zee B, Goodlow J, Johnston D, Smaldone L (1991): A randomized, double-blind study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. Ann Oncol 2:681-686.
22. + conductance in cardiac muscle. Naunyn Schmiedebergs Arch Pharmacol 335:692-696.
23. Scholtysik G, Imoto Y, Yatani A, Brown AM (1988): 5-Hydroxytryptamine antagonist ICS 205-930 blocks cardiac potassium, sodium and calcium currents. J Pharmacol Exp Ther 245:773-778.
24. Vaughan Williams EM (1989): Classification of antiarrhythmic actions. In Vaughan Williams EM (ed): Antiarrhythmic Drugs. Berlin: Springer-Verlag, pp 45-67.
25. Watanabe H, Hasegawa A, Shinozaki T, Arita S, Masaki C (1995): Possible cardiac side effects of granisetron, an antiemetic agent in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 35:278-282.
26. Williams FM, Rothaul AL, Kane KA, Parratt JR (1985): Antiarrhythmic and electrophysiological effects of ICS 205-930, an antagonist of 5-hydroxytryptamine at peripheral receptors. J Cardiovasc Pharmacol 7:550-555.
27. 3 receptor antagonists, in anesthetized dogs. Drug Dev Res 24:277-284.